Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
REDWOOD CITY, Calif., April 06, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2016 the compensation committee of the company’s board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company’s common stock with a per share exercise price of $13.30, the closing trading price on the grant date, and 3,725 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
